Snoring Control Devices Market: Trends and Forecasts up to 2024
Geographically, North America held the largest market share in snoring control devices market in 2017. The factors facilitating growth in this region includes increasing awareness regarding snoring control devices, rising geriatric population, high expenditure on wellness products, speedy adoption of new products and easy availability of snoring control devices in this region as compared to other regions. Asia Pacific region is anticipated to be the fastest growing region among others owing to rising awareness concerning the seriousness of the disease and increasing disposable income.
Segment Covered
The report on global snoring control devices market covers segments such as, product and distribution channel. On the basis of product the global snoring control devices market is categorized into tongue stabilizing devices, mandibular advancement devices, nasal devices, chin straps, position control devices and others. On the basis of distribution channel the global snoring control devices market is categorized into retail pharmacies and online stores.
Geographic Coverage
The countries covered in the North America region include the U. S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U. K., France, Spain, and Rest of Europe are included in the European region. The U. S. drives the growth in the North America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience a growth at a CAGR of x. x % over the period of 2018-2024.
Major Key Players Mentioned in this Premium Report
The report provides profiles of the companies in the global snoring control devices market such as, Sleeping Well, LLC. Apnea Sciences Corporation, The Pure Sleep Company, Somnomed Limited, Airway Management Inc., Theravent, Inc., Tomed Dr. Toussaint Gmbh, Glaxosmithkline, PLC, Meditas Ltd. and Innovative Health Technologies( NZ) Limited.
Report Highlights:
3 © Infinium Global Research